Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 2 Recruiting
60 enrolled
DEBRA
Phase 3 Recruiting
1,670 enrolled
EvoPAR-BR01
Phase 3 Recruiting
500 enrolled
CAMBRIA-1
Phase 3 Recruiting
4,300 enrolled
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Phase 2 Recruiting
81 enrolled
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Phase 2 Recruiting
30 enrolled
RaPhLRR
Phase 2 Recruiting
200 enrolled
RAMP 301
Phase 3 Recruiting
270 enrolled
IMPULSE
Recruiting
240 enrolled
ELEGANT
Phase 3 Recruiting
4,220 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Phase 2 Recruiting
400 enrolled
ELEGANCE
Recruiting
2,766 enrolled
OPERA-01
Phase 3 Recruiting
510 enrolled
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Phase 1 Recruiting
50 enrolled
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Phase 2 Recruiting
20 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
POWER II
Phase 3 Recruiting
354 enrolled
BFR-ESS
Phase 2 Recruiting
40 enrolled
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Phase 3 Recruiting
240 enrolled
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Phase 3 Recruiting
1,903 enrolled